Additionally, there is evidence that potent P2Y12 inhibition may offer benefits in patients with T2DM and complications such as lower extremity arterial disease, in which ticagrelor improves microvascular flow, for example [45]. Here, P2RY12 is linked to type 2 diabetes mellitus.